Comparative Pharmacology
Head-to-head clinical analysis: PROTONIX IV versus ZEGERID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROTONIX IV versus ZEGERID.
PROTONIX IV vs ZEGERID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion.
40 mg intravenously once daily for 7-10 days; for pathological hypersecretory conditions, initial dose 80 mg IV every 12 hours, titrate per acid output.
20 mg or 40 mg orally once daily before a meal.
None Documented
None Documented
1-2 hours in healthy subjects; prolonged to 3.5-8 hours in hepatic impairment.
1.0–1.5 hours in plasma; however, the pharmacodynamic half-life is longer due to irreversible inhibition of H+/K+-ATPase; drug effect persists for 24 hours after single dose.
Primarily hepatic metabolism; 71-82% of dose excreted in urine as metabolites, 18-20% in feces.
Approximately 82% renal (as metabolites), 18% fecal (via bile); less than 1% unchanged in urine.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor